NewsfeedFollowed Companies

Bristol Myers Squibb's Competitors, Revenue, Number of Employees, Funding and Acquisitions

Bristol-Myers Squibb is a biopharmaceutical firm that discovers, develops and delivers medicines for patients prevail ov... Read more

Based on data from Bristol Myers Squibb's latest SEC filings

Annual Revenue

Based on data from Bristol Myers Squibb's latest SEC filings

Employees

Giovanni Caforio's photo - Chairman & CEO of Bristol Myers Squibb

Chairman & CEO

Giovanni Caforio

CEO Approval Rating

88/100

OVERVIEW

Founded:

1858

Headquarters:

New YorkNew York

Status:

PublicIndependent Company of NYSEBMY

Industry Sector:

Pharmaceuticals

Biotechnology

SIC Code:

2834NAICS listing »

2836NAICS listing »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Amgen a competitor of Bristol Myers Squibb?

I don't know

Trending News for Bristol Myers Squibb and Bristol Myers Squibb's Competitors

December 10, 2019

Reuters

Bluebird bio, Bristol-Myers' multiple myeloma therapy shows promise in early study

Bluebird bio Inc and Bristol-Myers Squibb Co on Monday reported encouraging initial data from an ongo... See more »

Today 12:46 AM

Global Legal Chronicle

Merck's $2.7 Billion Acquisition of ArQule

Covington & Burling LLP acted as legal advisor to Merck & Co., Inc. and Skadden, Arps, Slate, Meagher... See more »

December 10, 2019

Seeking Alpha

Roche receives CE Mark for Accu-Chek SugarView app

See more »

Competitive Analysis

TOP COMPETITORS OR ALTERNATIVES

Merck has been one of Bristol Myers Squibb's top competitors. Merck was founded in 1891, and is headquartered in Kenilworth, New Jersey. Merck competes in the Pharmaceuticals industry. Merck generates $21.8B more revenue vs. Bristol Myers Squibb.

Roche is a top competitor of Bristol Myers Squibb. Roche is a Public company that was founded in Basel, Basel-Country in 1896. Like Bristol Myers Squibb, Roche also competes in the Biotechnology industry. Roche has 70,434 more employees vs. Bristol Myers Squibb.

Gilead is perceived as one of Bristol Myers Squibb's biggest rivals. Gilead was founded in 1987, and its headquarters is in Foster City, California. Gilead competes in the Specialty Pharmaceuticals field. Gilead has 12,300 fewer employees than Bristol Myers Squibb.

RANK

COMPANY

LEADERSHIP

CEO SCORE

EMPLOYEES

TOTAL FUNDING

REVENUE

Giovanni Caforio

Chairman & CEO

- -
23,300
$0
$24.2B
1

Kenneth C. Frazier

Chairman & CEO

68/100
69,000
- -
$46B
2

Severin Schwan

CEO

78/100
94,052
- -
$927.4M
3

Daniel O’Day

Chairman & CEO

56/100
11,000
$86.3M
$22.4B
4

Albert Bourla

CEO

69/100
92,400
- -
$53B
5

Robert A. Bradway

Chairman & CEO

67/100
19,200
$19M
$23.4B
6

Emma Walmsley

CEO

74/100
99,827
- -
$40.4B
7

Pascal Soriot

CEO

63/100
59,700
- -
$21.9B
8

David A. Ricks

Chairman & CEO

71/100
38,680
- -
$24.9B
9

Vasant Narasimhan

CEO

61/100
118,393
- -
$50.3B
10

Richard A. Gonzalez

Chairman & CEO

86/100
109
$3.8B
$22.3M
The top 10 competitors in Bristol Myers Squibb's competitive set are Merck, Roche, Gilead, Pfizer, Amgen, GSK, AstraZeneca, Eli Lilly, Novartis and AbbVie. Together they have raised over 3.9B between their estimated 640.9K employees. Bristol Myers Squibb has 23,300 employees and is ranked 8th among it's top 10 competitors. The top 10 competitors average 56,878.

Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$24.2B

Bristol Myers Squibb's revenue is the ranked 6th among it's top 10 competitors. The top 10 competitors average 27.9B. Over the last four quarters, Bristol Myers Squibb's revenue has grown by 0.6%. Specifically, in Q3 2019's revenue was $6B; in Q2 2019, it was $6.3B; in Q1 2019, it was $5.9B; in Q4 2018, Bristol Myers Squibb's revenue was $6B.

Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
Celgene Corporation

Jan 2019

Source »
$74B
Celgene develops and commercializes novel therapies for the treatment of cancer and inflammatory diseases.
IFM Therapeutics, LLC

Aug 2017

Source »
$300M
IFM is a biopharmaceutical company that develops and commercializes small molecule therapies for the treatment of cancer and inflammatory disorders.
Cormorant Pharmaceuticals

Jul 2016

Source »
$500M
Cormorant Pharmaceuticals engages in the research and development of therapeutics for the treatment of cancer and rare diseases.
Padlock Therapeutics, Inc.

Mar 2016

Source »
$225M
Padlock Therapeutics researches, discovers, develops and commercializes drugs for protein arginine deiminases.
Cardioxyl Pharmaceuticals, Inc.

Nov 2015

Source »
$300M
Cardioxyl Pharmaceuticals engages in the discovery and development of therapies and technologies for the treatment of cardiovascular diseases.

These are all the companies that Bristol Myers Squibb has acquired. Bristol Myers Squibb has acquired 12 companies and its latest acquisition was Celgene Corporation in Jan 2019. Celgene develops and commercializes novel therapies for the treatment of cancer and inflammatory diseases.

Investments

COMPANY

DESCRIPTION

AMOUNT

INVESTMENT DATE

ROUND

EXIT DATE

PathAI is an AI-based platform that develops pathology research solutions to treat and diagnose cancer and infectious diseases.
$15M
Nov 03, 2019
Series B
-
Vedanta is a biotechnology company that develops and commercializes novel therapies for the treatment of immune-mediated diseases.
$16.6M
Sep 10, 2019
Series C
-
Vedanta is a biotechnology company that develops and commercializes novel therapies for the treatment of immune-mediated diseases.
$18.5M
May 12, 2019
Series C
-
Vedanta is a biotechnology company that develops and commercializes novel therapies for the treatment of immune-mediated diseases.
$27M
Dec 23, 2018
Series C
-
Galecto Biotech develops galectin modulators for the treatment of fibrosis and cancer.
$90M
Oct 25, 2018
Series C
Nov 01, 2014

These are all the companies that Bristol Myers Squibb has invested in. Bristol Myers Squibb has invested 12 companies and its latest investment was Celgene Corporation in Jan 2019. Celgene develops and commercializes novel therapies for the treatment of cancer and inflammatory diseases.

Bristol Myers Squibb News

December 10, 2019Seeking Alpha

Bristol-Myers Squibb (BMY) Presents At American Society Of Hematology Annual Meeting - Slideshow

See more »
December 10, 2019PharmaLive

Bristol-Myers Squibb, bluebird bio, Oryzon and More

Hundreds of studies and results were presented at the 61st American Society of Hematology (ASH) Annua... See more »
December 10, 2019BioPortfolio

BristolMyers Squibb Presents Overall Survival and Safety Data From Pivotal CC486 Study QUAZAR AML001

Maintenance treatment with CC486 resulted in a significant improvement in overall survival compared w... See more »
December 10, 2019The Pharma Letter

Bristol-Myers updates on Reblozyl at ASH

US pharma major Bristol-Myers Squibb presented data from multiple studies evaluating Reblozyl (luspat... See more »
December 10, 2019Reuters

Bluebird bio, Bristol-Myers' multiple myeloma therapy shows promise in early study

Bluebird bio Inc and Bristol-Myers Squibb Co on Monday reported encouraging initial data from an ongo... See more »
December 10, 2019MarketWatch

Investors shift attention to next generation of CAR-T, new sickle cell treatments at major hematology meeting

A handful of sickle cell disease treatments and CAR-T therapies that treat cancer have been approved ... See more »
December 9, 2019BioPortfolio

STAT Plus BristolMyers CMO on cell therapies This is the best time to be in drug development

"You have emerging therapies that are changing the curve of life and transforming patient outcomes" s... See more »

Bristol Myers Squibb Press Releases

August 26, 2019Business Wire

Bristol-Myers Squibb Announces Agreement Between Celgene and Amgen to Divest OTEZLA® for $13.4 Billion

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that Celgene Corp... See more »
March 6, 2019streetinsider

Bristol-Myers Squibb to Take Part in the Barclays 2019 Global Healthcare Conference

Bristol-Myers Squibb Company (NYSE: BMY) will take part in a fireside chat at the Barclays 2019 Globa... See more »
February 12, 2019CENTRALCHARTS

Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Celgene Corporation - CELG

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti... See more »
January 14, 2019StreetInsider

European Commission Approves Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) for First-Line Treatment of Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission has approved th... See more »
January 8, 2019PR Newswire

Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Celgene Corporation - CELG

NEW ORLEANS, Jan. 8, 2019 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., ... See more »
January 7, 2019PR Newswire

Mirati Announces Clinical Collaboration With Bristol-Myers Squibb For The Planned Phase 3 Trial In Non-Small Cell Lung Cancer To Evaluate Sitravatinib In Combination With Nivolumab (OPDIVO®)

SAN DIEGO, Jan. 7, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) a clinical-stage tar... See more »
January 4, 2019GlobalNewswire

Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Celgene Corporation to Bristol-Myers Squibb Company is Fair to Shareholders

NEW YORK, Jan. 04, 2019 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsins... See more »

Bristol Myers Squibb Videos

April 30, 2019Bristol Myers Squibb Youtube Channel

"Cambridge: A Culture of Collaboration" on YOUTUBE

See more »
April 4, 2019Bristol Myers Squibb Youtube Channel

"Quality & Compliance | Biologics Careers at Devens, MA | Bristol-Myers Squibb" on YOUTUBE

See more »
January 25, 2019Bristol Myers Squibb Youtube Channel

"Making a Molecule" on YOUTUBE

See more »
January 7, 2019Bristol Myers Squibb Youtube Channel

"Running the Lab" on YOUTUBE

See more »
January 7, 2019Bristol Myers Squibb Youtube Channel

"Inclusion Through the Eyes of Our Leaders" on YOUTUBE

See more »
November 2, 2018Bristol Myers Squibb Youtube Channel

"The Body's First Line of Defense" on YOUTUBE

See more »
October 26, 2018Bristol Myers Squibb Youtube Channel

"Bristol-Myers Squibb: Driving Scientific Discovery for Patients" on YOUTUBE

See more »

Social Statistics

Headquarters

430 E 29th Street 14th Floor

New York, New York10016

1-800-332-2056

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Bristol-Myers Squibb is a biopharmaceutical firm that discovers, develops and delivers medicines for patients prevail over serious diseases. Bristol Myers Squibb was founded in 1858. Bristol Myers Squibb's headquarters is located in New York, New York...

CEO

Bristol Myers Squibb's Chairman & CEO, Giovanni Caforio, currently has an approval rating of 88%. Bristol Myers Squibb's primary competitors are Merck, Roche & Gilead.

Website

bms.com

Frequently Asked Questions about Bristol Myers Squibb

  1. When was Bristol Myers Squibb founded?

    Bristol Myers Squibb was founded in 1858

  2. Who is Bristol Myers Squibb's CEO?

    Bristol Myers Squibb's CEO is Giovanni Caforio

  3. How much revenue does Bristol Myers Squibb generate?

    Bristol Myers Squibb generates $24.2B in revenue

  4. How much funding does Bristol Myers Squibb have?

    Bristol Myers Squibb has historically raised $0 in funding

  5. Where is Bristol Myers Squibb's headquarters?

    Bristol Myers Squibb's headquarters is in New York New York, USA

  1. How many employees does Bristol Myers Squibb have?

    Bristol Myers Squibb has 23,300 employees

  2. What sector does Bristol Myers Squibb operate in?

    Bristol Myers Squibb is in Pharmaceuticals, Biotechnology

  3. Who are Bristol Myers Squibb's competitors?

    Bristol Myers Squibb's top competitors are Merck, Roche, Gilead

  4. Who has Bristol Myers Squibb invested in?

    Bristol Myers Squibb's has invested in companies such as PathAI, Vedanta, Vedanta
Stay up-to-date with the latest news on Bristol Myers Squibb